Last reviewed · How we verify
Perindopril plus Amlodipine
Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation.
Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while amlodipine blocks L-type calcium channels in vascular smooth muscle to cause vasodilation. Used for Hypertension, Hypertension in patients with coronary artery disease.
At a glance
| Generic name | Perindopril plus Amlodipine |
|---|---|
| Sponsor | University of Abuja |
| Drug class | ACE inhibitor + Calcium channel blocker combination |
| Target | ACE (angiotensin-converting enzyme) and L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination of an ACE inhibitor and a calcium channel blocker. Perindopril prevents the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Amlodipine independently dilates blood vessels by blocking calcium influx into smooth muscle cells. Together, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Hypertension in patients with coronary artery disease
Common side effects
- Cough
- Peripheral edema
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. (PHASE3)
- Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.
- Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perindopril plus Amlodipine CI brief — competitive landscape report
- Perindopril plus Amlodipine updates RSS · CI watch RSS
- University of Abuja portfolio CI